With Competition Closing In, Novo Details Oral Semaglutide Weight Loss At ADA

Lilly’s Oral GLP-1 Also Impressed

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Novo’s oral semaglutide generated 15.1% weight loss at 68 weeks in the Phase IIIa OASIS 1 study, but Lilly’s orforglipron provided up to 14.7% weight loss at 36 weeks in Phase II without reaching a plateau. 

Measuring tape on a wood background
Novo's oral semaglutide measures up well with Wegovy in obesity • Source: Shutterstock

The race to bring an oral obesity agent to market is heating up. Novo Nordisk A/S presented detailed results for the oral version of its GLP-1 agonist semaglutide on 25 June at the American Diabetes Association (ADA) annual meeting from the Phase IIIa OASIS 1 clinical trial, with 15.1% mean weight loss observed in overweight and obese adults versus 2.4% for placebo (p<0.0001), confirming="" topline="" results="" release="" in="" may.="" the="" readout="" took="" place="" two="" days="" after="" the="" presentation="" of="" phase="" ii="" data="" at="" ada="" for="" [c#136:eli="" lilly="" and="" company]’s="" oral="" glp-1="" drug="" orforglipron,="" which="" could="" be="" a="" formidable="">

Overweight and obese adults treated with the highest dose of orforglipron achieved weight loss of 14.7% at 36 weeks in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D